Abstract C068: Construction of preclinical study model for optimal anticancer drug selection using PDX model in pancreatic cancer

Abstract

Abstract Background: Translational research using the patient-derived xenograft (PDX) model is progressing rapidly and is also becoming widespread in pancreatic cancer research. Since PDX models retain the characteristics and the heterogeneity of the primary tumor, PDX models can be reflected in the effectiveness of the anticancer drug in human. The purpose of this study was to establish the PDX library of pancreatic cancer for preclinical study. Methods: The tissues of the pancreatic cancer were obtained from patients who underwent surgery at our hospital. Two PDX models were established using immunodeficient rats. One case was effective in gemcitabine plus nab-paclitaxel (GnP) therapy, and the other was ineffective in GnP therapy in preoperative treatment. 5-FU, CPT-11, L-OHP, GEM, and CDDP were administered to these PDX models once a week for 3 weeks. The primary endpoint was tumor shrinkage. Results: GEM was effective in PDX model in a case in which GnP therapy was effective in the clinical setting, in contrast, GEM was ineffective in PDX model in a case in which GnP was ineffective in the clinical setting. This result was correlated with actual clinical practice. Conclusions: In this study, single anticancer drug tests were performed on PDX models using immunodeficient rats. The efficacy of anticancer drugs was correlated with the clinical setting, indicating that our PDX models might be useful as a preclinical study model. We are currently conducting multi anticancer drug studies. Citation Format: Ryota Tanaka, Kenjiro Kimura, Naoki Tani, Shimpei Eguchi, Ken Kageyama, Shuhei Kushiyama, Shigeaki Kurihara, Masahiko Kinoshita, Kohei Nishio, Hiroji Shinkawa, Go Ohira, Akira Yamamoto, Takeaki Ishizawa. Construction of preclinical study model for optimal anticancer drug selection using PDX model in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C068.